GRAIL, LLC Q3 2026 Earnings Recap

GRAIL shares fell 17.1% after earnings, with investors likely focused on Q3 test-volume growth slowing to 24% year over year amid NHS-Galleri-related negative headlines and competition. Management said those factors tempered growth, while the FDA decision is still expected by early Q1 2027.

Key Takeaways

• Q3 test volumes rose 24% year over year; GRAIL completed more than 174,000 tests in the first three quarters, up 36% from the prior year.
• Management described Q3 as seasonally slow and said negative coverage of NHS-Galleri results and a highly active competitive market also tempered growth.
• Galleri received a favorable FDA advisory committee vote; the company expects a final FDA decision by early Q1 2027.
• In NHS-Galleri, adding Galleri to standard screening detected 4–6.5 times more cancers through screening, but did not reduce combined Stage III and IV cancers; management cited a 20% reduction in Stage IV disease in a prespecified group of 12 cancers.
• GRAIL expanded its provider sales force in June, rolled out its first Epic integration at quarter-end, and expects several more integrations by year-end.